XML 26 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Goodwill and Intangible Assets, Net
 3 Months Ended
Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets, Net Goodwill and Intangible Assets, Net
Goodwill
The Company evaluates goodwill for impairment on an annual basis in the first fiscal quarter, and more frequently if indicators for potential impairment exist. Goodwill impairment testing is conducted at the reporting unit level, which is generally defined as an operating segment or one level below an operating segment (also known as a component), for which discrete financial information is available and segment management regularly reviews the operating results of that reporting unit. The annual impairment testing performed in fiscal 2025 and fiscal 2024 did not indicate any impairment of goodwill.
Changes in the carrying amount of goodwill were as follows:
(In millions)U.S. PharmaceuticalPrescription Technology SolutionsMedical-Surgical Solutions
International
Total
Balance, March 31, 2024$4,123 $2,024 $2,536 $1,449 $10,132 
Foreign currency translation adjustments, net— — — (14)(14)
Balance, June 30, 2024$4,123 $2,024 $2,536 $1,435 $10,118 
Intangible Assets
Information regarding intangible assets was as follows:
 June 30, 2024March 31, 2024
(Dollars in millions)Weighted-
Average
Remaining
Amortization
Period
(Years)		Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount		Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships11$1,825 $(730)$1,095 $1,830 $(701)$1,129 
Service agreements101,129 (690)439 1,126 (676)450 
Trademarks and trade names12755 (405)350 759 (395)364 
Technology10284 (129)155 284 (125)159 
Other732 (26)6 34 (26)8 
Total  $4,025 $(1,980)$2,045 $4,033 $(1,923)$2,110 
All intangible assets were subject to amortization as of June 30, 2024 and March 31, 2024. Amortization expense of intangible assets was $63 million and $62 million for the three months ended June 30, 2024 and 2023, respectively. Estimated amortization expense of the assets listed in the table above is as follows: $183 million, $214 million, $207 million, $203 million, and $200 million for the remainder of fiscal 2025 and each of the succeeding years through fiscal 2029, respectively, and $1.0 billion thereafter.